2,230
Participants
Start Date
January 21, 2016
Primary Completion Date
February 21, 2018
Study Completion Date
March 28, 2018
ETC-1002
ETC-1002 180 mg tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
Placebo
Matching placebo tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
Huntsville
Cottonwood
Phoenix
Canoga Park
Santa Rosa
Bridgeport
Hartford
Atlantis
Boca Raton
Crestview
Crystal River
Daytona Beach
Lake Worth
Miami Lakes
Tampa
Park Ridge
Iowa City
Overland Park
Covington
Louisville
Minden
Monroe
Shreveport
Auburn
Midland
Saginaw
Saint Cloud
Tupelo
Jefferson City
Nashua
Bridgewater
Cary
Mount Airy
Raleigh
Rocky Mount
Wilmington
Cincinnati
Sandusky
Willoughby
Hillsboro
Fort Worth
Houston
Katy
Kingwood
Orem
Richmond
Puyallup
Tacoma
Vancouver
Victoria
Gatineau
Mississauga
Oshawa
Peterborough
Scarborough Village
Chicoutimi
Gatineau
Longueuil
Montreal
Québec
Saint-Charles-Borromée
Saint-Jean-sur-Richelieu
Berlin
Bochum
Dresden
Essen
Frankfurt
Leipzig
München
Amsterdam
Arnhem
Eindhoven
Goes
Groningen
Hardenberg
Leiden
Rotterdam
Tilburg
Venlo
Zutphen
Gdansk
Gdynia
Katowice
Krakow
Lodz
Lowicz
Poznan
Puławy
Torun
Wroclaw
Bexhill-on-Sea
Birmingham
Cardiff
Chesterfield
Chichester
Chippenham
Chorley
Glasgow
Hexham
Hull
Ipswich
Liverpool
Manchester
Reading
Lead Sponsor
Esperion Therapeutics, Inc.
INDUSTRY